A previous model used to quantify hepatitis B virus (HBV) disease burden and vaccination impact estimated the total number of persons who died from HBV-related causes for the year 2000. However, there have been significant changes in HBV epidemiology since 2000, including an increase in infant vaccine coverage to 90.5% in 2016, high disease burden from foreign-born persons, and an emerging epidemic among adults with a history of incarceration and/or who inject drugs. In 2016, 14.7% of liver transplant recipients tested positive for HBV. This project aims to estimate annual US chronic hepatitis B mortality (all-cause and cause-specific) and associated costs in the present year (2018) and possibly at a future time point (2038).